"The company is one of several biotech firms aiming to use
mesenchymal stem cells as a potential COVID-19 treatment.
Cleveland-based Athersys, which is working on stem cell therapies
for strokes, heart disease and other conditions, is also expected to
begin clinical trials soon. Haifa, Israel-based Pluristem, which is
developing stem cell treatments as well, secured 50 million Euro
(about $55.4 million) in financing this week from the European
Investment Bank to support its COVID-19 trials."
News 
Market Data 
Discover 
